Genfit S.A. (NASDAQ:GNFT) Sees Significant Growth in Short Interest

Genfit S.A. (NASDAQ:GNFT) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 63,400 shares, an increase of 6.0% from the December 15th total of 59,800 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 10,100 shares, the days-to-cover ratio is presently 6.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Genfit in a research note on Friday, October 11th.

Genfit Trading Up 1.9 %

Shares of GNFT stock traded up $0.07 during trading hours on Friday, hitting $3.51. The company had a trading volume of 3,904 shares, compared to its average volume of 6,150. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a 12 month low of $3.33 and a 12 month high of $6.42. The firm’s fifty day moving average is $3.97 and its 200 day moving average is $4.49.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.